Orbimed Advisors LLC Decreases Holdings in BioAge Labs, Inc. $BIOA

Orbimed Advisors LLC cut its stake in BioAge Labs, Inc. (NASDAQ:BIOA) by 10.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 711,811 shares of the company’s stock after selling 79,090 shares during the quarter. Orbimed Advisors LLC’s holdings in BioAge Labs were worth $12,450,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new stake in shares of BioAge Labs in the third quarter valued at about $27,000. CWM LLC lifted its position in BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after acquiring an additional 1,053 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares in the last quarter. Walleye Capital LLC purchased a new position in BioAge Labs in the 2nd quarter worth approximately $64,000. Finally, Bank of America Corp DE boosted its holdings in BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after acquiring an additional 3,517 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BIOA shares. BTIG Research began coverage on shares of BioAge Labs in a research note on Wednesday, May 13th. They set a “buy” rating and a $40.00 price objective on the stock. Wall Street Zen downgraded shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Finally, Roth Capital began coverage on shares of BioAge Labs in a report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BioAge Labs presently has an average rating of “Moderate Buy” and an average price target of $43.50.

BioAge Labs Price Performance

BIOA stock opened at $21.77 on Monday. The stock’s 50 day moving average is $20.26 and its two-hundred day moving average is $19.37. BioAge Labs, Inc. has a 52-week low of $4.11 and a 52-week high of $25.95. The company has a market capitalization of $967.74 million, a PE ratio of -9.07 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The business had revenue of $2.77 million during the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. As a group, sell-side analysts anticipate that BioAge Labs, Inc. will post -2.68 EPS for the current year.

BioAge Labs Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.